Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST)
Acute Stroke · Cerebrovascular Accident
Enrolment: 50 · Results not recorded
Loading the evidence…
Drug · Candesartan is a selective, noncompetitive antagonist of the type-1 angiotensin II receptor (AT1), preventing angiotensin II-mediated vasoconstriction and lowering blood pressure without altering heart rate; direct interaction true, disease efficacy true. It is given clinically as the prodrug candesartan cilexetil (CHEMBL1014, max_phase 4, first approval 1998, black box warning for foetal toxicity), hydrolysed to candesartan during gastrointestinal absorption. ChEMBL ATC C09CA06.
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Acute Stroke · Cerebrovascular Accident
Enrolment: 50 · Results not recorded
Healthy
Enrolment: 24 · Results not recorded
Hypertension · Cholesterolemia
Enrolment: 219 · Results not recorded
Cocaine Dependence
Enrolment: 30 · Results not recorded
Essential Hypertension
Enrolment: 384 · Results not recorded
Breast Cancer · Heart Failure
Enrolment: 130 · Results not recorded
Hypertension
Enrolment: 32 · Results not recorded
Hypertension
Enrolment: 300 · Results not recorded
Essential Hypertension
Enrolment: 1773 · Results not recorded
2 studies reported at therapy level; 2 evidence entries itemised.
Model: Experimental ischaemic stroke (cerebral ischaemia/reperfusion)
Repurposed candesartan, minocycline and atorvastatin each reduced infarct size, improved neurological outcome and decreased haemorrhagic transformation after experimental stroke.
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.
Model: Reperfused myocardial infarction with assessment during the healing phase to day 25
Both candesartan and omapatrilat attenuated infarct-related increases in SLPI, matricellular proteins, angiotensin II, inflammatory and matrix remodelling mediators and left ventricular remodelling, and normalised the fall in IL-10.
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.